Lucid Diagnostics inks strategic partnership with UpScriptHealth

  • PAVmed (PAVM) company Lucid Diagnostics has entered into a definitive agreement with UpScriptHealth related to the company's EsoGuard test.
  • UpScriptHealth to provide telemedicine services to evaluate consumers with chronic heartburn seeking early esophageal precancer detection using Lucid’s EsoGuard test.
  • Lucid believes its EsoGuard and EsoCheck are capable of serving as a widespread screening tool to prevent esophageal cancer deaths, through the early detection of esophageal precancer in at-risk GERD patients.

    • Sector news
    Intuitive Surgical's sales on record level according analysts' estimates
    KBC Securities Initiates Research Coverage of ONWARD® Medical with a Buy Rating and Target Price of EUR 10.00 Per Share
    Analysts: L'Oreal on steam for record sales
    Analysts count on revenue increase Ontex
    Analysts: this year best year ever for McKesson
    ONWARD® ARC Therapy™ Highlighted at 2024 Annual Meeting of the North American Neuromodulation Society (NANS)
    ONWARD® TO PARTICIPATE IN BASEL HEALTHTECH CONFERENCE 2024
    National news
    Analysts anticipate for 2024 on revenue increase AutoNation
    Stock Exxon Mobil goes ahead in America in terms of dividend yields
    Analysts expect over 2024 revenue increase Intel
    Analysts expect over 2024 revenue increase Alphabet
    Gilead Sciences in top American dividend stocks
    Analysts expect record sales Lockheed Martin
    Analysts: more sales Halliburton
    Press news
    DATAGROUP Reorganizes Management Board and Top Management Structure for the Next Stage of Growth
    Baader Bank reports excellent results in first quarter of 2024
    Drägerwerk AG & Co. KGaA: Dräger with solid business performance in the first quarter of 2024
    ANDRITZ reports stable results for the first quarter of 2024
    Symrise sees successful start into the 2024 fiscal year (news with additional features)
    Befesa builds momentum quarter-on-quarter and forecasts full-year EBITDA between €195m and €235m for 2024
    TAKKT AG: TAKKT strengthens resilience in the first quarter
    Logoanalist
    Returns European stocks
    Crypto currencies information
    About us Network Partners
    Fpgroup.nlinfo@analist.nlRSS feedContactIntellectual Property Photos Analist.nlLinksISIN
  • Glossary
    		• MorningstarPrudena.comAAII.comNASDAQvwd GroupEuronextBATS Chi-xBats
    ©2024 ValueSpectrum. All Rights Reserved
    Developed and maintained by  Velainn logo